Elan Shares Climb on $3.25B Biogen's Tysabri Deal

Feb. 6 (Bloomberg) -- Bloomberg's Caroline Hyde reports on what is next for Elan Corp. as Biogen Idec Inc. agreed to acquire the company's stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties. She speaks on Bloomberg Television's "The Pulse."
Voting ‘No’ Means No More Euros in Greece: Schmieding
15:43 - Berenberg Chief Economist Holger Schmieding and Bloomberg View Columnist Mark Gilbert discuss the referendum in Greece and possible ramifications from a ‘no’ vote. They speak with Francine Lacqua and Manus Cranny on Bloomberg Television’s “The Pulse.” (Source: Bloomberg)
  • Can China Catch the Falling Knife in Equity Markets?
  • Greek 'Yes' Campaigners Have Momentum: Piccoli
  • The German Media’s Spin on the Greek Crisis